Beijing Strong Biotechnologies, Inc. (300406.SZ)
CNY 15.07
(-1.76%)
CNY 15.07
(-1.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 411.59 Million CNY | -45.97% |
| 2022 | 761.77 Million CNY | 2.67% |
| 2021 | 741.97 Million CNY | 367.79% |
| 2020 | -277.07 Million CNY | -103.96% |
| 2019 | -135.84 Million CNY | 67.35% |
| 2018 | -416.13 Million CNY | 33.03% |
| 2017 | -621.41 Million CNY | 19.46% |
| 2016 | -771.51 Million CNY | -14.99% |
| 2015 | -670.95 Million CNY | -4.09% |
| 2014 | -644.61 Million CNY | -243.58% |
| 2013 | -187.61 Million CNY | -27.57% |
| 2012 | -147.06 Million CNY | -89.99% |
| 2011 | -77.41 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 134.95 Million CNY | -67.21% |
| 2024 Q3 | 167.13 Million CNY | 0.97% |
| 2024 Q2 | 171.03 Million CNY | 26.74% |
| 2023 Q3 | 721.32 Million CNY | -13.06% |
| 2023 Q4 | 411.59 Million CNY | -42.94% |
| 2023 Q1 | 794.35 Million CNY | 4.28% |
| 2023 Q2 | 829.71 Million CNY | 4.45% |
| 2023 FY | 411.59 Million CNY | -45.97% |
| 2022 Q4 | 761.77 Million CNY | -6.39% |
| 2022 FY | 761.77 Million CNY | 2.67% |
| 2022 Q2 | 798.61 Million CNY | -2.45% |
| 2022 Q1 | 818.64 Million CNY | 10.33% |
| 2022 Q3 | 813.79 Million CNY | 1.9% |
| 2021 Q4 | 741.97 Million CNY | 61.91% |
| 2021 Q1 | -201.86 Million CNY | 27.14% |
| 2021 Q2 | -101.76 Million CNY | 49.59% |
| 2021 FY | 741.97 Million CNY | 367.79% |
| 2021 Q3 | 458.26 Million CNY | 550.33% |
| 2020 Q4 | -277.07 Million CNY | -123.32% |
| 2020 Q3 | -124.06 Million CNY | -237.08% |
| 2020 Q2 | -36.8 Million CNY | 65.09% |
| 2020 Q1 | -105.44 Million CNY | 22.38% |
| 2020 FY | -277.07 Million CNY | -103.96% |
| 2019 Q2 | -492.57 Million CNY | 5.35% |
| 2019 Q4 | -135.84 Million CNY | 70.32% |
| 2019 Q1 | -520.41 Million CNY | -25.06% |
| 2019 FY | -135.84 Million CNY | 67.35% |
| 2019 Q3 | -457.73 Million CNY | 7.07% |
| 2018 Q3 | -507.51 Million CNY | -11.5% |
| 2018 FY | -416.13 Million CNY | 33.03% |
| 2018 Q4 | -416.13 Million CNY | 18.0% |
| 2018 Q2 | -455.16 Million CNY | 14.53% |
| 2018 Q1 | -532.55 Million CNY | 14.3% |
| 2017 Q3 | -592.79 Million CNY | -6.42% |
| 2017 Q4 | -621.41 Million CNY | -4.83% |
| 2017 FY | -621.41 Million CNY | 19.46% |
| 2017 Q1 | -823.96 Million CNY | -4.01% |
| 2017 Q2 | -557.03 Million CNY | 32.4% |
| 2016 Q2 | -660.54 Million CNY | 5.73% |
| 2016 Q4 | -792.19 Million CNY | -9.46% |
| 2016 FY | -771.51 Million CNY | -14.99% |
| 2016 Q1 | -700.68 Million CNY | -0.46% |
| 2016 Q3 | -723.72 Million CNY | -9.56% |
| 2015 Q2 | -635.15 Million CNY | 2.55% |
| 2015 Q4 | -697.45 Million CNY | -7.06% |
| 2015 Q3 | -651.44 Million CNY | -2.57% |
| 2015 Q1 | -651.73 Million CNY | -1.1% |
| 2015 FY | -670.95 Million CNY | -4.09% |
| 2014 Q2 | -236.66 Million CNY | -226.14% |
| 2014 Q4 | -644.61 Million CNY | -136.02% |
| 2014 Q3 | -273.11 Million CNY | -15.4% |
| 2014 Q1 | 187.61 Million CNY | 200.0% |
| 2014 FY | -644.61 Million CNY | -243.58% |
| 2013 Q4 | -187.61 Million CNY | 0.0% |
| 2013 FY | -187.61 Million CNY | -27.57% |
| 2012 FY | -147.06 Million CNY | -89.99% |
| 2011 FY | -77.41 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 68.78% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 110.132% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | 412.709% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | 148.382% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | 340.989% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | 270.957% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | 158.111% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | 111.32% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | 543.853% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | 184.589% |